Literature DB >> 33895333

Manufacturing of bacteriophages for therapeutic applications.

Jorge João1, João Lampreia2, Duarte Miguel F Prazeres3, Ana M Azevedo4.   

Abstract

Bacteriophages, or simply phages, are the most abundant biological entities on Earth. One of the most interesting characteristics of these viruses, which infect and use bacteria as their host organisms, is their high level of specificity. Since their discovery, phages became a tool for the comprehension of basic molecular biology and originated applications in a variety of areas such as agriculture, biotechnology, food safety, veterinary, pollution remediation and wastewater treatment. In particular, phages offer a solution to one of the major problems in public health nowadays, i.e. the emergence of multidrug-resistant bacteria. In these situations, the use of virulent phages as therapeutic agents offers an alternative to the classic, antibiotic-based strategies. The development of phage therapies should be accompanied by the improvement of phage biomanufacturing processes, both at laboratory and industrial scales. In this review, we first present some historical and general aspects related with the discovery, usage and biology of phages and provide a brief overview of the most relevant phage therapy applications. Then, we showcase current processes used for the production and purification of phages and future alternatives in development. On the production side, key factors such as the bacterial physiological state, the conditions of phage infection and the operation parameters are described alongside with the different operation modes, from batch to semi-continuous and continuous. Traditional purification methods used in the initial phage isolation steps are then described followed by the presentation of current state-of-the-art purification approaches. Continuous purification of phages is finally presented as a future biomanufacturing trend.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Bacteriophage biomanufacturing; Bacteriophage therapy; Bacteriophages; Downstream bioprocessing; Purification; Upstream bioprocessing

Mesh:

Substances:

Year:  2021        PMID: 33895333     DOI: 10.1016/j.biotechadv.2021.107758

Source DB:  PubMed          Journal:  Biotechnol Adv        ISSN: 0734-9750            Impact factor:   14.227


  2 in total

Review 1.  Essential Topics for the Regulatory Consideration of Phages as Clinically Valuable Therapeutic Agents: A Perspective from Spain.

Authors:  Roberto Vázquez; Roberto Díez-Martínez; Pilar Domingo-Calap; Pedro García; Diana Gutiérrez; Maite Muniesa; María Ruiz-Ruigómez; Rafael Sanjuán; María Tomás; María Ángeles Tormo-Mas; Pilar García
Journal:  Microorganisms       Date:  2022-03-26

Review 2.  A Phage Foundry Framework to Systematically Develop Viral Countermeasures to Combat Antibiotic-Resistant Bacterial Pathogens.

Authors:  Vivek K Mutalik; Adam P Arkin
Journal:  iScience       Date:  2022-03-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.